Related Experiment Video
Updated: Aug 11, 2026

Vessel-Sparing Microsurgical Longitudinal Intussusception Vasoepididymostomy to Treat Epididymal Obstructive Azoospermia
Published on: May 27, 2022
Male idiopathic oligoasthenoteratozoospermia
1Operative Unit of Andrology, Società Italiana di Medicina della Riproduzione, Via Mazzini 12, 40138 Bologna, Italy. giorgiocavallini@libero.it
Abstract:
Idiopathic oligoasthenoteratozoospermia (iOAT) affects approximately 30% of all infertile men. This mini-review discussed recent data in this field. Age, non-inflammatory functional alterations in post-testicular organs, infective agents (Chlamydia trachomatis, herpes virus and adeno-associated viruses), alterations in gamete genome, mitochondrial alterations, environmental pollutants and "subtle" hormonal alterations are all considered possible causes of iOAT. Increase of reactive oxygen species in tubules and in seminal plasma and of apoptosis are reputed to affect sperm concentration, motility and morphology. iOAT is commonly diagnosed by exclusion, nevertheless spectral traces of the main testicular artery may be used as a diagnostic tool for iOAT. The following can be considered therapies for iOAT: 1) tamoxifen citrate (20 mg/d) + testosterone undecanoate (120 mg/d) (pregnancy rate per couple/month [prcm]: 3.8%); 2) folic acid (66 mg/d) + zinc sulfate (5 mg/d); 3) L-carnitine (2 g/d) alone or in combination with acetyl-L-carnitine (1 g/d) (prcm: 2.3%); and 4) both carnitines = one 30 mg cinnoxicam suppository every 4 days (prcm: 8.5%). Alpha-blocking drugs improved sperm concentration but not morphology, motility or pregnancy rate. Tranilast (300 mg/d) increased sperm parameters and pregnancy rates in an initial uncontrolled study. Its efficacy on sperm concentration (but not on sperm motility, morphology or prcm) was confirmed in subsequent published reports. The efficacy of tamoxifen + testosterone undecanoate, tamoxifen alone, and recombinant follicle-stimulating hormone is still a matter for discussion.
Insights
Idiopathic oligoasthenoteratozoospermia (iOAT), affecting 30% of infertile men, has multiple potential causes including infections and environmental factors. Therapies like carnitines and cinnoxicam show promise for improving male fertility outcomes.
Area of Science:
- Reproductive Medicine
- Urology
- Andrology
Background:
- Idiopathic oligoasthenoteratozoospermia (iOAT) is a significant cause of male infertility, impacting approximately 30% of affected men.
- Potential iOAT causes include age, post-testicular organ dysfunction, infections (Chlamydia trachomatis, herpes, adeno-associated viruses), gamete and mitochondrial DNA alterations, environmental pollutants, and subtle hormonal imbalances.
- Increased reactive oxygen species and apoptosis are implicated in reduced sperm concentration, motility, and morphology.
Purpose of the Study:
- To review recent data on the causes, diagnosis, and therapeutic options for idiopathic oligoasthenoteratozoospermia (iOAT).
- To evaluate the efficacy of various treatments for iOAT, focusing on sperm parameters and pregnancy rates.
Main Methods:
- This mini-review synthesized recent research findings on iOAT.
- Diagnostic approaches discussed include exclusion criteria and spectral traces of the main testicular artery.
- Therapeutic interventions analyzed include tamoxifen citrate, testosterone undecanoate, folic acid, zinc sulfate, L-carnitine, acetyl-L-carnitine, cinnoxicam, alpha-blocking drugs, and tranilast.
Main Results:
- Several factors are considered potential causes of iOAT, with oxidative stress and apoptosis playing key roles.
- Therapies evaluated showed varying effects: cinnoxicam (8.5% pregnancy rate per couple/month), L-carnitine (2.3%), and tamoxifen + testosterone undecanoate (3.8%).
- Alpha-blocking drugs improved sperm concentration, while tranilast showed promise for sperm parameters and pregnancy rates in initial studies, though its efficacy requires further confirmation.
Conclusions:
- iOAT is a complex condition with multifactorial origins, often diagnosed by exclusion.
- Certain therapeutic agents, particularly cinnoxicam and combinations involving carnitines, demonstrate potential in improving fertility outcomes for men with iOAT.
- Further research is needed to definitively establish the efficacy of treatments like tamoxifen, testosterone undecanoate, and recombinant FSH for iOAT.
Related Concept Videos
Infertility in Males
Spermatogenesis
Oogenesis
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...